Antibiotic therapy for skin and soft tissue infections: a comparative analysis of investigations of the efficacy and safety of a new-generation oxazolidinone class drug


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The review gives data on the clinical efficacy and safety of SIVEXTRO® (tedizolid), a new oxazolidinone-class drug. Tedizolid is highly effective in treating gram-positive skin and soft tissue infections (erysipelas, acute cellulitis, skin abscess, wound infections with a lesion size area of at least 75 cm2) and, according to the 2013 FDA guidelines, are considered as acute bacterial infections of the skin and its structures. The ESTABLISH-1 has compared the efficacy and tolerability of a 6-day cycle of treatment with 200-mg once-per-day dose of tedizolid with a 10-day cycle with 600-mg twice-per-day dose of linezolid. The ESTABLISH-2 study has compared 200-mg once-per-day dose of intravenous/oral tedizolid for 6 days with 600-mg twice-per-day dose of intravenous/oral linezolid for 10 days. The investigation has revealed that the 6-day cycle of treatment with tedizolid is as effective as the 10-day cycle with linezolid and demonstrated the best tolerability.

Full Text

Restricted Access

About the authors

E. G Fokina

Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human WellBeing

Email: e-fokina@yandex.ru
Cand. Med. Sci, Infectious Disease Physician, Scientific Advisory Clinical Diagnostic Center 3a, Novogireevskaya St., Moscow 111123, Russia Telephone: +7(495) 788-00-02

References

  1. Хирургические инфекции кожи и мягких тканей. Российские национальные рекомендации. М., 2009. 92 с.
  2. Zilberberg M.D., Shorr A.F., Micek S.T. et al. Epidemiology and outcomes of hospitalizations with complicated skin and skin-structure infections: implications of healthcare -associated infection risk factors. Infect. Control. Hosp. Epidemiol. 2009; 30(12): 1203-10.
  3. Lipsky B.A., Moran G.J., Napolitano L.M. et al. A prospective, multicenter, observational study of complicated skin and soft tissue infections in hospitalized patients: clinical characteristics, medical treatment, and outcomes. BMC Infect. Dis. 2012; (12): 227 (Р. 1-12) http://www.biomedcentral.com/1471-2334/12/227.
  4. Stevens D.L., Bisno A.L., Chambers H.F. et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin. Infect. Dis. 2014; 59: 147-59.
  5. May A.K. Skin and soft tissue infections. Surg. Clin. North. Am. 2009; 89(2): 403-20.
  6. Kozlov R.S., Krechikova O.I., Ivanchik N.V. et al. Etiology of Nosocomial Bacterial Infections in Russia. Rosnet Study Group. Proceedings of the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy. 25-28 October, 2008. Washington, DC, USA.; 572, abst. K-4108
  7. Dryden M.S. Complicated skin and soft tissue infection. J. Antimicrob. Chemother. 2010; 65(Suppl. 3): 11135-44.
  8. Di Nubile M.J., Lipsky B.A. Complicated infections of skin and skin structures: when the infection is more than skin deep. J. Antimicrob. Chemother. 2004; 53 (Supрl.2):: 1137-50.
  9. Ратникова Л.И., Шип С.А. Современные клиниколабораторные и гендерные особенности рожи. Эпидемиол. и инфекц. бол. 2013; (3): 19-21.
  10. Фокина Е.Г., Рослый И.М., Потекаева С.А. Лабораторная оценка рожистого воспаления. Эпидемиол. и инфекц. болезни. Актуал. вопр. 2014; (1): 28-32.
  11. Larru B., Gerber J.S. Cutaneous bacterial infections caused by Staphylococcus aureus and Streptococcus pyogenes in infants and children. Pediatr. Clin. N. Am. 2014; 61: 457-78.
  12. Gunderson C.G., Martinello R.A. A systematic review of bacteriemias in cellulitis and erysipeals. J. Infect. 2012; 64: 148-55.
  13. Eriksson B., Jorup-Ronstrom C., Karkkonen K., Sjoblom A.C., Holm S.E. Erysipelas: clinical and bacteriologic spectrum and serological aspects. Clin. Infect. Dis. 1996; 23(5): 1091-8.
  14. Троицкий В.И., Еровиченков А.А., Потекаева С.А., Свистунова Т.С., Белая О.Ф., Волчкова Е.В. Разнообразие выявляемых возбудителей у больных рожей. Эпидемиол. инфекц. бол. 2015; (2): 34-7.
  15. Cosgrove S., Sakoulas G., Perencevich E. et al. Comparison of mortality associated with methicillin-resistantand methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin. Infect. Dis. 2003; 36: 53-9.
  16. Ramakrishnan K., Salinas R., Higuita NIA. Skin and soft tissue infections. Am. Family Phys. 2015; 92(6): 474-83.
  17. Дибиров М.Д., Гаджимуратов Р.У, Лебедев В.В., Терещенко С.А. Выбор антибактериальной терапии при лечении гнойных осложнений синдрома диабетической стопы. Инфекции в хирургии 2009; 12(11): 113-7.
  18. Белобородов В.Б. Современные принципы применения левофлоксацина в лечении инфекций кожи и мягких тканей. Consilium medicum 2009; (1): 38-42.
  19. Bowler P. Duerden B. Armstrong D. Wound microbiology and associated approaches to wound management. Clin. Microbiol Rev. 2001; 14 (2): 244-69.
  20. Еровиченков А.А., Домонова Э.А., Потекаева С.А., Свистунова Т.С., Матосова С.В., Шипулина О.Ю., Малолетнева Н.В., Шипулин Г.А., Пак С.Г. Современные молекулярно-биологические методы в изучении этиологии буллезно-геморрагической формы рожи нижних конечностей. Инфекционные болезни 2016; 14(2): 6-12.
  21. Bally M., Dendukuri N., Sinclair A., Ahern S.P., Poisson M., Brophy J. A network meta-analysis of antibiotics for treatment of hospitalised patients with suspected or proven meticillin-resistant Staphylococcus aureus infection. Int. J. Antimicrob. Agents 2012; 40(6): 479-95.
  22. Logman J.F., Stephens J., Heeg B. et al. Comparative effectiveness of antibiotics for the treatment of MRSA complicated skin and soft tissue infections. Curr. Med. Res. Opin. 2010; 26(7): 1565-78.
  23. Bounthavong M., Hsu D.I. Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): a meta-analysis. Curr. Med. Res. Opin. 2010; 26(2): 407-21.
  24. Beibei L., Yun C., Mengli C., Nan B., Xuhong Y., Rui W. Linezolid versus vancomycin for the treatment of gram- positive bacterial infections: meta-analysis of randomised controlled trials. Int. J. Antimicrob. Agents 2010; 35(1): 3-12.
  25. Lin D.F., Zhang YY., Wu J.F. et al. Linezolid for the treatment of infections caused by Gram-positive pathogens in China. Int. J. Antimicrob. Agents 2008; 32(3): 241-9.
  26. Kohno S., Yamaguchi K., Aikawa N. et al. Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan. J. Antimicrob. Chemother. 2007; 60(6): 1361-9.
  27. Food and Drug Administration. Guidance for Industry, Uncomplicated and Complicated Skin and Skin Structure Infections - Developing Antimicrobial Drugs for Treatment. 1998. https://www.fda.gov/ohrms/dockets/98fr/2566dft.pdf
  28. Food and Drug Administration. Guidance for Industry Acute Bacterial Skin and Skin Structure Infections: Developing Drugs for Treatment. 2013. http://www.fda.gov/downloads/Dmgs/../Guidances/.
  29. Picazo J. Betriu C., Rodrhuez-Avial I. et al. Vigilancia de resistencias a los antimicrobianos: Estudio VIRA. Enferm. Infect. Microbiol. Clin. 2002; 20: 503-10.
  30. Rybak J., Roberts K. Tedizolid phosphate: a next-generation oxazolidinone. Infect. Dis. Ther. 2015; (4): 1-14.
  31. Amin A., Cerceo A., Deitelzweig B. et al. Hospitalist perspective on the treatment of skin and soft tissue infections. Mayo Clin. Proc. 2014; 1-16.
  32. Prokocimer P., De Anda C., Fang E. et al. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA 2013; 309: 559-69.
  33. Moran G.J., Fang E., Corey G.R. et al. Tedizolid for 6 days vs linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect. Dis. 2014; 14(8): 696-705.
  34. Shorr A., Lodise T., Corey G.R. et al. Analysis of the phase 3 ESTABLISH trials: tedizolid versus linezolid in acute bacterial skin and skin structure infection. Antimicrob. Agents Chemother. 2015; 59(2): 864-71. doi: 10.1128/AAC.03688-14.
  35. Im W.B., Choi S.H., Park J.Y., Choi S.H., Finn J., Yoon S.H. Discovery of torezolid as a novel 5-hydroxymethyl-oxazolidinone antibacterial agent. Eur. J. Medicine Chem. 2011; 46(4): 1027-39.
  36. Ye Hui, Lü Xiaoju. Tedizolid for treatment of acute bacterial skin and skin structure infections. Expert Review of Anti-infective Therapy 2015; 13(9): 1051-60.
  37. Sahre M., Sabarinath S., Grant M. et al. Skin and soft tissue concentrations of tedizolid (formerly torezolid), a novel oxazolidinone, following a single oral dose in healthy volunteers. Int. J. Antimicrob. Agents 2012; 40(1): 51-4.
  38. Lemaire S., van Bambeke F., Appelbaum P.C., Tulkens P.M. Cellular pharmacokinetics and intracellular activity of torezolid (TR-700): studies with human macrophage (THP-1) and endothelial (HUVEC) cell lines. J. Antimicrob. Chemother. 2009; 64(5): 1035-43.
  39. Drusano G.L., Liu W., Kulawy R., Louie A. Impact of granulocytes on the antimicrobial effect of tedizolid in a mouse thigh infection model. Antimicrob. Agents Chemother. 2011; 55(11): 5300-5.
  40. Housman S.T., Pope J.S., Russomanno J. et al. Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers. Antimicrob. Agents Chemother. 2012; 56(5): 2627-34.
  41. Jones R.N., Moet G.J., Sader H.S. et al. TR-700 in vitro activity against and resistance mutation frequencies among Gram-positive pathogens. J. Antimicrob. Chemother. 2009; 63(4): 716-20.
  42. Flanagan S., McKee E.E., Das D., Tulkens P.M., Hosako H., Fiedler-Kelly J., Passarell J., Radovsky A., Prokocimer P. Evaluation of the Potential of Tedizolid and Linezolid to Affect Mitochondrial Function Using Nonclinical and Pharmacokinetic Assessments. Antimicrob Agents Chemother. 2015; 59(1): 178-85.
  43. Locke J.B., Hilgers M., Shaw K.J. Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700). Antimicrob. Agents Chemother. 2009; 53(12): 5265-74.
  44. Locke J.B., Morales G., Hilgers M. et al. Elevated linezolid resistance in clinical cfr-positive Staphylococcus aureus isolates is associated with co-occurring mutations in ribosomal protein L3. Antimicrob. Agents Chemother. 2010: 54(12): 5352-5.
  45. Flanagan S.D., Bien P.A., Munoz K.A. et al. Pharmacokinetics of tedizolid following oral administration: single and multiple dose, effect of food, and comparison of two solid forms of the prodrug. Pharmacotherapy 2014; 34(3): 240-50.
  46. Flanagan S., Fang E., Munoz KA. et al. Single- and Multiple-Dose Pharmacokinetics and Absolute Bioavailability of Tedizolid. Pharmacotherapy 2014; 34: 891-900.
  47. Prokocimer P., Bien P., Munoz K.A. et al. Hematological Effects of TR-701, Linezolid and Placebo Administered for 21 Days in Healthy Subjects. Presented at 48th Interscience Conference on Antimicrobial Agents and Chemotherapy. 25-28 October, 2008. Washington, DC, USA. Poster F1-2069a.
  48. Flanagan S., Passarell J., Lu Q. et al. Tedizolid population pharmacokinetics, exposure response, and target attainment. Antimicrob. Agents Chemother. 2014; 58(11): 6462-70.
  49. Flanagan S., Bartizal K., Minassian S.L. et al. In vitro, in vivo and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions. Antimicrob. Agents Chemother. 2013; 57(7): 3060-6.
  50. Ong V., Flanagan S., Fang E. et al. Absorption, distribution, metabolism and excretion of the novel antibacterial prodrug tedizolid phosphate. Drug Metab. Dispos. 2014; 42(8): 1275-84
  51. Fang E. Characterization of neurologic and ophthalmologic safety of oral administration of tedizolid for up to 21 days in healthy volunteers. American Journal of Therapeutics 2017; 24 (2): 227- 33.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies